VERU INC (VERU) Stock Price, Quote, News and Overview
NASDAQ:VERU - Nasdaq - US92536C1036 - Common Stock - Currency: USD
VERU Quote, Performance and Key Statistics
0.5342
+0.01 (+1.71%)
The current stock price of VERU is 0.5342 USD. In the past month the price increased by 5.82%. In the past year, price decreased by -59.22%.
VERU Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 64.61 | 796.27B | ||
| JNJ | JOHNSON & JOHNSON | 15.67 | 379.48B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 16.83 | 257.82B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.96 | 218.96B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.29 | 209.55B | ||
| MRK | MERCK & CO. INC. | 10.21 | 196.28B | ||
| PFE | PFIZER INC | 7.12 | 125.57B | ||
| SNY | SANOFI-ADR | 11.41 | 124.61B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 43.18 | 100.17B | ||
| GSK | GSK PLC-SPON ADR | 8.32 | 72.88B | ||
| ZTS | ZOETIS INC | 25.11 | 66.32B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.98 | 46.47B |
Related stock screener links
About VERU
Company Profile
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company is headquartered in Miami, Florida and currently employs 210 full-time employees. Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Company Info
VERU INC
2916 N. Miami Avenue, Suite 1000
Miami FLORIDA 33127 US
CEO: Mitchell S. Steiner
Employees: 189
Company Website: https://verupharma.com/
Investor Relations: https://ir.verupharma.com/
Phone: 13125959123
VERU INC / VERU FAQ
What is the stock price of VERU INC today?
The current stock price of VERU is 0.5342 USD. The price increased by 1.71% in the last trading session.
What is the ticker symbol for VERU INC stock?
The exchange symbol of VERU INC is VERU and it is listed on the Nasdaq exchange.
On which exchange is VERU stock listed?
VERU stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERU INC stock?
11 analysts have analysed VERU and the average price target is 2.81 USD. This implies a price increase of 425.08% is expected in the next year compared to the current price of 0.5342. Check the VERU INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERU INC worth?
VERU INC (VERU) has a market capitalization of 78.20M USD. This makes VERU a Micro Cap stock.
How many employees does VERU INC have?
VERU INC (VERU) currently has 189 employees.
What are the support and resistance levels for VERU INC (VERU) stock?
VERU INC (VERU) has a support level at 0.53 and a resistance level at 0.54. Check the full technical report for a detailed analysis of VERU support and resistance levels.
Is VERU INC (VERU) expected to grow?
The Revenue of VERU INC (VERU) is expected to decline by -78.96% in the next year. Check the estimates tab for more information on the VERU EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERU INC (VERU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VERU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VERU, evaluating the profitability, health, valuation and growth aspects
- VERU INC (VERU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERU INC (VERU) Sales and EPS estimates to see what analysts future expectations are.
- VERU INC (VERU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERU INC (VERU) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERU INC (VERU) Stock Chart to make your own analysis
- VERU INC (VERU) Latest news and press-releases to stay up to date.
Does VERU INC (VERU) stock pay dividends?
VERU does not pay a dividend.
When does VERU INC (VERU) report earnings?
VERU INC (VERU) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of VERU INC (VERU)?
VERU INC (VERU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
What is the Short Interest ratio of VERU INC (VERU) stock?
The outstanding short interest for VERU INC (VERU) is 11.51% of its float. Check the ownership tab for more information on the VERU short interest.
VERU Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VERU. When comparing the yearly performance of all stocks, VERU is a bad performer in the overall market: 92.95% of all stocks are doing better.
VERU Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VERU. Both the profitability and financial health of VERU have multiple concerns.
VERU Financial Highlights
Over the last trailing twelve months VERU reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 67.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.57% | ||
| ROE | -116.97% | ||
| Debt/Equity | 0.27 |
VERU Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to VERU. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 17.67% and a revenue growth -78.96% for VERU